FrancophonIA/ELRC3.0 huggingface dataset:
English: NAME OF THE MEDICINAL PRODUCT Augmentin and associated names (see Annex I) 250 mg/125 mg dispersible tablets [See Annex I - To be completed nationally] Amoxicillin/clavulanic acid
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 250 mg/125 mg disperzibilne tablete [glejte Dodatek I - Izpolni država članica] amoksicilin/klavulanska kislina
English: PHARMACEUTICAL FORM Prolonged release tablet.
Slovenian: obliko in ga nadaljevati s peroralno obliko.
English: Add water in 2 portions up to the mark on the bottle label (60 ml) Add 72 ml of water (or add water in 2 portions up to the mark) (80 ml) Add 90 ml of water (or add water in 2 portions up to the mark) (100 ml) Invert and shake well
Slovenian: Dodajte 72 ml vode (ali dodajte vodo v dveh delih do oznake) (80 ml).
English: Dose Mean peak serum conc (g/ml)
Slovenian: v serumu (g/ml)
English: • inflammation o f tubes in th
Slovenian: • vnetje cevk v ledvicah,
English: NAME OF THE MEDICINAL PRODUCT Augmentin and associated names (see Annex I) 250 mg/125 mg film-coated tablets [See Annex I - To be completed nationally] Amoxicillin/clavulanic acid
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 250 mg/125 mg filmsko obložene tablete [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: 500 mg/125 mg film-coated tablets Film-coated tablet.
Slovenian: 500 mg/125 mg filmsko obložene tablete filmsko obložena tableta [Izpolni država članica]
English: 250 mg/125 mg dispersible tablets Dispersible tablet.
Slovenian: 250 mg/125 mg disperzibilne tablete disperzibilna tableta [Izpolni država članica]
English: Lithuania - Augmentin ES Poland - Augmentin ES
Slovenian: Litva - Augmentin ES
English: Augmentin and associated names (see Annex I) 2000 mg/200 mg powder for solution for infusion [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 2000 mg/200 mg prašek za raztopino za infundiranje [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: Augmentin and associated names (see Annex I) 600 mg/42.9 mg/5 ml powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 600 mg/42,9 mg/5 ml prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: Augmentin and associated names (see Annex I) 250 mg/25 mg powder for solution for injection or infusion [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 250 mg/25 mg prašek za raztopino za injiciranje ali infundiranje [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: 500 mg/125 mg dispersible tablets Dispersible tablet.
Slovenian: 500 mg/125 mg disperzibilne tablete disperzibilna tableta [Izpolni država članica]
English: NAME OF THE MEDICINAL PRODUCT Augmentin and associated names (see Annex I) 500 mg/125 mg dispersible tablets [See Annex I - To be completed nationally] Amoxicillin/clavulanic acid
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 500 mg/125 mg disperzibilne tablete [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: Augmentin and associated names (see Annex I) 250 mg/31.25 mg powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 250 mg/31,25 mg prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: Augmentin and associated names (see Annex I) 250 mg/25 mg powder for solution for injection/in fusion} {Augmentin and associated names (see Annex I) 500 mg/50 mg powder for solution for injection/infusion}
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 250 mg/25 mg prašek za raztopino za injiciranje ali infundiranje [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina za intravensko uporabo
English: No adjustment in Augmentin dose is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.
Slovenian: Bolnikom z očistkom kreatinina (CrCl) nad 30 ml/min odmerka zdravila Augmentin ni treba prilagoditi.
English: Augmentin and associated names (see Annex I) 250 mg/62.5 mg/5 ml powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 250 mg/62,5 mg/5 ml prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: 250 mg/31.25 mg and 500 mg/62.5 mg powder for oral suspension in sachets
Slovenian: 250 mg/31,25 mg prašek za peroralno suspenzijo v vrečkah, 500 mg/62,5 mg prašek za peroralno suspenzijo v vrečkah
English: Augmentin and associated names (see Annex I) 50 mg/12.5 mg/ml powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 50 mg/12,5 mg/ml prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: 250 mg/25 mg powder for solution for injection or infusion in
Slovenian: 250 mg/25 mg prašek za raztopino za injiciranje ali infundiranje Nemčija - Augmentan
English: Adults and children  40 kg CrCl: 10-30 ml/min 500 mg/125 mg twice daily CrCl < 10 ml /min
Slovenian: Odrasli in otroci  40 kg CrCl 10-30 ml/min
English: Formulation
Slovenian: Oblika
English: Augmentin 250 mg/125 mg dispersible tablets are not recommended in children < 40 kg. 125 mg/62.5 mg/5 ml powder for oral suspension
Slovenian: 250 mg/125 mg disperzibilne tablete Augmentin 250 mg/125 mg disperzibilne tablete niso priporočljive za otroke < 40 kg.
English: Augmentin and associated names (see Annex I) 500 mg/100 mg powder for solution for injection or infusion [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 500 mg/100 mg prašek za raztopino za injiciranje ali infundiranje [glejte Dodatek I - izpolni država članica]] amoksicilin/klavulanska kislina
English: • inflammation of
Slovenian: • bruhanje,
English: Augmentin and associated names (see Annex I) 125 mg/31.25 mg/ml powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 125 mg/31,25 mg/ml prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: Augmentin and associated names (see Annex I) 125 mg/62.5 mg/ml powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 125 mg/62,5 mg/ml prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: Augmentin and associated names (see Annex I) 500 mg/50 mg powder for solution for injection or infusion [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 500 mg/50 mg prašek za raztopino za injiciranje ali infundiranje [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: 2000 mg/200 mg powder for solution for infusion This medicinal product contains 125.9 mg (5.5 mmol) of sodium per per vial or bottle.
Slovenian: 2000 mg/200 mg prašek za raztopino za infundiranje To zdravilo vsebuje 39,3 mg (1,0 mmol) kalija na vialo ali stekleničko.
English: NAME OF THE MEDICINAL PRODUCT Augmentin and associated names (see Annex I) 875 mg/125 mg powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 875 mg/125 mg prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: 250 m 1 g/3 .25 mg powder for oral suspension in sachets Franc A e - ugmentin
Slovenian: 250 mg/31,25 mg prašek za peroralno suspenzijo v vrečkah Francija - Augmentin
English: The pharmacokinetic results for a study, in which amoxicillin/clavulanic acid (250 mg/125 mg tablets three times daily) was administered in the fasting state to groups of healthy volunteers are presented below.
Slovenian: Spodaj so predstavljeni farmakokinetični rezultati študije, v kateri so amoksicilin/klavulansko kislino (250 mg/125 mg tablete) na tešče uporabili v skupinah zdravih prostovoljcev.
English: This should be considered if you are on a controlled sodiu m diet.
Slovenian: Če ste na dieti z nadzorovanim vnosom natrija, morate to upoštevati.
English: Lot
Slovenian: AUC
English: com hese may affect up to 1 in 100 people ncommon side effects that may show up in blood tests:
Slovenian: če opazite katerega od teh simptomov, se morate nujno posvetovati z zdravnikom Redki neželeni učinki, ki se lahko pokažejo na preiskavah krvi:
English: If you forget to give your child a dose, give it as soon as y child the next dose too soon, but wait about 4 hour
Slovenian: Če ste otroku pozabili dati odmerek zdravila, mu ga dajte, čim se spomnite.
English: Augmentin and associated names (see Annex I) 250 mg/62.5 mg/ml powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 250 mg/62,5 mg/ml prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally] {Name and address}
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET {DD mesec LLLL} [glejte Dodatek I - izpolni država članica]
English: Augmentin 125 mg/62.5 mg/5 ml powder for oral suspension contains 2.5 mg of aspartame (E951) per ml, a source of phenylalanine.
Slovenian: 125 mg/62,5 mg/5 ml prašek za peroralno suspenzijo Zdravilo Augmentin 125 mg/62,5 mg/5 ml prašek za peroralno suspenzijo vsebuje na 1 ml 2,5 mg aspartama (E951), ki je vir fenilalanina.
English: • Community acquired pneumonia.
Slovenian: • pljučnica, dobljena v domačem okolju.
English: WHAT IT IS USED FOR
Slovenian: Uporabno do: {MM LLLL}
English: If your child still feels unwell they doctor.
Slovenian: Če se še vedno ne počutite dobro, ponovno obiščite zdravnika.
English: If you forget to give your child a dose, give it as so child the next dose too soon, but wait about 4 hours before giving the next dose.
Slovenian: Naslednjega odmerka mu ne smete dati prezgodaj, temveč počakajte približno 4 ure, preden vzame naslednji odmerek.
English: Augmentin and associated names (see Annex I) 125 mg/31.25 mg powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 125 mg/31,25 mg prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: PHARMACEUTICAL FORM Powder for oral suspension.
Slovenian: FARMACEVTSKA OBLIKA prašek za peroralno suspenzijo [Izpolni država članica]
English: Intermediate
Slovenian: Uporabljeno
English: Augmentin and associated names (see Annex I) 500 mg/62.5 mg powder for oral suspension [See Annex I - To be completed nationally]
Slovenian: Augmentin in povezana imena (glejte Dodatek I) 500 mg/62,5 mg prašek za peroralno suspenzijo [glejte Dodatek I - izpolni država članica] amoksicilin/klavulanska kislina
English: {MM/YYYY}.
Slovenian: • prebavil,
English: If y ur child stops taking Augmentin
Slovenian: Otrok naj neha jemati zdravilo Augmentin.
English: gm rks.
Slovenian: Cmax tmax
English: 6 July 2012
Slovenian: 6. julij 2012
English: This change was to be recognised in the Netherlands and all other
Slovenian: To spremembo bi bilo treba odobriti na Nizozemskem in v vseh drugih zadevnih državah članicah.
English: Outcome of a procedure under Article 6(12) of Regulation (EC) 1084/2003 as amended
Slovenian: Izid postopka iz člena 6 (12) Uredbe 1084/2003/ES, kakor je bila spremenjena.
English: Because the Member States were not able to reach an agreement on this new indication, on 28 and 29 June 2011 the Italian and Swedish medicines regulatory agencies referred the matter to the CHMP for arbitration.
Slovenian: Ker se države članice niso uspele sporazumeti o tej novi indikaciji, sta italijanska in švedska regulativna agencija za zdravila 28. in 29. junija 2011 zadevo poslali odboru CHMP v arbitražo.
English: The Committee reviewed the two main studies presented by the company to support the new indication.
Slovenian: Odbor je pregledal dve glavni študiji, ki jih je za podporo nove indikacije predložila družba Bayer B.V.
English: The grounds for the referral were concerns over whether the medicines' benefits in the combined indication outweighed their risks, particularly the risk of venous thromboembolism (VTE, formation of blood clots in the veins).
Slovenian: Razlog za napotitveni postopek so bili pomisleki glede tega, ali so koristi zdravil pri kombinirani indikaciji večje od tveganj, predvsem od tveganja za vensko trombembolijo (VTE, tvorbo krvnih strdkov v venah).
English: They contain two active substances, ethinylestradiol and drospirenone, which are derived from natural hormones produced in the ovaries: ethinylestradiol is derived from oestrogen and drospirenone is derived from progesterone.
Slovenian: Vsebujeta dve zdravilni učinkovini, etinilestradiol in drospirenon, pridobljeni iz naravnih hormonov, ki jih tvorijo jajčniki: etinilestradiol je pridobljen iz estrogena in drospirenon iz progesterona.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) had been asked to consider a proposed change to the marketing authorisations for these medicines to include a new indication for the treatment of moderate acne in women seeking oral contraception.
Slovenian: Odbor za zdravila za humano uporabo (CHMP) pri Evropski agenciji za zdravila je bil naprošen, naj pregleda predlagano spremembo dovoljenja za promet s tema zdraviloma, ki vključuje novo indikacijo za zdravljenje zmernih aken pri ženskah, ki želijo uporabljati peroralno kontracepcijo.
English: 1 Yaz is authorised in all EU Member States except Hungary, and Ethinylestradiol-Drospirenone 24+4 is authorised in the following Member States: Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Malta, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom.
Slovenian: Zdravilo Yaz je odobreno v vseh državah članicah EU, razen na Madžarskem, zdravilo Ethinylestradiol-Drospirenone 24+4 pa je odobreno v naslednjih državah članicah: v Avstriji, Bolgariji, na Cipru, Češkem, Danskem, Finskem, v Franciji,
English: The Committee concluded that the change to the marketing authorisations cannot be granted.
Slovenian: Odbor je sklenil, da spremembe dovoljenja za promet z zdraviloma ni mogoče odobriti.
English: Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 are authorised in several Member States of the European Union (EU)1 under a mutual recognition procedure on the basis of an initial authorisation granted by the Netherlands.
Slovenian: Zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 sta po postopku medsebojnega priznavanja na podlagi prvotnega dovoljenja, odobrenega na Nizozemskem, odobreni v več državah članicah Evropske unije (EU)1.
English: The Committee concluded that the variation to the marketing authorisations for these medicines cannot be approved.
Slovenian: Odbor je sklenil, da spremembe dovoljenja za promet s tema zdraviloma ni mogoče odobriti.
English: Therefore, based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP considered that the benefits of Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 did not outweigh their risks in the proposed new indication.
Slovenian: Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave znotraj odbora je odbor CHMP sklenil, da koristi zdravil Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 pri na novo predlagani indikaciji niso večje od tveganj, povezanih z njima.
English: The European Commission issued the decisions on 3 July 2012 (Yaz 24+4) and 6 July 2012 (Ethinylestradiol-Drospirenone 24+4).
Slovenian: Evropska komisija je sklepa izdala 3. julija 2012 (Yaz 24+4) in 6. julija 2012 (EthinylestradiolDrospirenone 24+4).
English: Women not seeking contraception would therefore be unnecessarily exposed to the risks of Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 when alternative acne treatments are available.
Slovenian: Ženske, ki ne želijo prejemati peroralne kontracepcije, bi bile tako po nepotrebnem izpostavljene tveganjem pri zdravilih Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4, kadar so na voljo alternativne oblike zdravljenja aken.
English: Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 work by changing the body's hormonal balance to prevent ovulation, by altering the mucus in the cervix (neck of the womb) and by thinning the endometrium (the lining of the womb).
Slovenian: Zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 delujeta tako, da spremenita hormonsko ravnovesje v telesu, saj spremenita sluznico v materničnem vratu in stanjšata endometrij (maternično sluznico), kar prepreči ovulacijo.
English: The company applied for a change to the marketing authorisations of these medicines to extend their use to include the ‘treatment of moderate acne vulgaris only in women seeking oral contraception'.
Slovenian: zdraviloma, da bi razširila njuno uporabo tako, da bi vključila indikacijo „zdravljenje navadnih zmernih aken samo pri ženskah, ki želijo prejemati peroralno kontracepcijo“.
English: Questions and answers on Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 (ethinylestradiol / drospirenone, 0.02 mg/3 mg tablets) EMA/550781/2012
Slovenian: Vprašanja in odgovori za zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 (etinilestradiol/drospirenon, 0,02 mg/3 mg tablete) EMA/257547/2012
English: On 19 April 2012, the European Medicines Agency completed an arbitration procedure for Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4.
Slovenian: Evropska agencija za zdravila je 19. aprila 2012 končala postopek arbitraže za zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4.
English: The Committee also considered the known risks with Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4, including VTE.
Slovenian: Odbor je prav tako upošteval znana tveganja, povezana z zdraviloma Yaz 24+4 in EthinylestradiolDrospirenone 24+4, vključno z VTE.
English: Questions and answers on Yaz 24+4 and EthinylestradiolDrospirenone 24+4 (ethinylestradiol / drospirenone, 0.02 mg/3 mg tablets)
Slovenian: Vprašanja in odgovori za zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 (etinilestradiol/drospirenon, 0,02 mg/3 mg tablete)
English: The CHMP noted the overall effectiveness of Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 compared with placebo in the treatment of acne.
Slovenian: Odbor CHMP je upošteval splošno učinkovitost zdravil Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 pri zdravljenju aken v primerjavi s placebom.
English: Why were Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 reviewed?
Slovenian: Zakaj sta bili zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 pregledani?
English: Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 are combined contraceptive pills.
Slovenian: Zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 sta kombinirani kontracepcijski tableti.
English: Since acne is a common problem in young women, the CHMP was concerned that the measures proposed by the company to ensure that these medicines would be used to treat acne only in women seeking oral contraception were not sufficient.
Slovenian: Ker so akne pogosta težava pri mladih ženskah, je odbor CHMP menil, da ukrepi, ki jih je družba Bayer B.V.
English: The company that markets Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4 is Bayer B.V.
Slovenian: Zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4 trži družba Bayer B.V.
English: What are Yaz 24+4 and Ethinylestradiol-Drospirenone 24+4?
Slovenian: Kaj sta zdravili Yaz 24+4 in Ethinylestradiol-Drospirenone 24+4?
English: This product information is the outcome of the referral procedure to which this Commission decision relates.
Slovenian: Te informacije o zdravilu so nastale na podlagi napotitvenega postopka, na katerega se nanaša ta sklep Komisije.
English: The valid product information is the final version achieved during the Coordination group procedure.
Slovenian: Veljavne informacije o zdravilu predstavljajo dokončno različico, ki je bila sprejeta v okviru postopka koordinacijske skupine.
English: • if you gave birth less than a few weeks ago.
Slovenian: • če ste pred manj kot nekaj tedni rodili.
English: Seek urgent medical attention
Slovenian: Nujno medicinsko pomoč poiščite
English: • Sensitivity to sunlight.
Slovenian: • občutljivost na sončno svetlobo.
English: • Wait until you get your menstrual period.
Slovenian: • Počakajte, da dobite menstruacijo.
English: There was no significant effect of cool water on these parameters.
Slovenian: Hladna voda ni pomembno vplivala na te parametre.
English: • This usually stops after the first few cycles.
Slovenian: • Te ponavadi prenehajo po prvih nekaj ciklih.
English: Are you experiencing any of these signs?
Slovenian: Ali imate katerega od teh znakov?
English: Women should be advised not to smoke if they wish to use a CHC.
Slovenian: Ženskam je treba svetovati, da naj ne kadijo, če želijo uporabljati CHC.
English: The frequency and nature of examinations should be based on established practice guidelines and be adapted to the individual woman.
Slovenian: Pogostnost in naravo pregledov je treba določiti na temelju uveljavljenih smernic za prakso in ju prilagoditi posamezni ženski.
English: In both cases, the number of VTEs per year is fewer than the number expected in women during pregnancy or in the postpartum period.
Slovenian: V obeh primerih je število VTE na leto manjše od števila, ki se pričakuje pri ženskah med nosečnostjo ali v obdobju po porodu.
English: The net effect of these changes may be clinically relevant in some cases.
Slovenian: Končen učinek teh sprememb je lahko v nekaterih primerih klinično pomemben.
English: Always use condoms to protect yourself from these diseases.
Slovenian: Za zaščito pred temi boleznimi vedno uporabljajte kondome.
English: It is important to tell your doctor if any of these conditions apply to you, even if you are unsure.
Slovenian: Pomembno je, da zdravniku poveste, ali katero od teh stanj velja za vas, tudi če niste prepričani.
English: Do not put on a patch this week.
Slovenian: ta teden obliža ne uporabljajte.
English: Recovery from blood clots is not always complete.
Slovenian: Okrevanje od krvnih strdkov ni vedno popolno.
English: VTE may be fatal in 1-2% of cases.
Slovenian: VTE se v 1-2% primerov lahko konča s smrtjo.
English: However, this may be due to other causes including sexually-transmitted disease.
Slovenian: To je lahko posledica drugih dejavnikov, vključno s spolno prenosljivimi boleznimi.
English: • Problems sleeping (insomnia)
Slovenian: • težave s spanjem (nespečnost)
English: It is used to prevent pregnancy.
Slovenian: Uporablja se za preprečevanje nosečnosti.
English: The following interactions have been reported in the literature.
Slovenian: Spodnje interakcije so bile navedene v literaturi.
English: Symptoms most commonly occur in one eye:
Slovenian: Simptomi, ki se najpogosteje pojavijo na enem očesu:
English: • Do not try to put a patch back on if:
Slovenian: • Obliža ne poskušajte ponovno namestiti, če:
English: • sudden trouble seeing in one or both eyes;
Slovenian: • nenadne težave z vidom na enem ali obeh očesih;
English: Number of VTE events per 10,000 women in one year
Slovenian: Število dogodkov VTE na 10.000 žensk v enem letu
English: Particularly important to consider if other risk factors also present.
Slovenian: Zlasti pomembno je, da se upošteva, če obstajajo tudi drugi dejavniki tveganja.
English: The safety and efficacy has been established in women aged 18 to 45 years.
Slovenian: Njegovo varnost in učinkovitost so dokazali pri ženskah med 18. in 45. letom starosti.
English: For more than 2 days (48 hours or more):
Slovenian: več kot 2 dneva (48 ur ali več):
English: Particularly important in women with additional risk factors.
Slovenian: To je pomembno zlasti za ženske z dodatnimi dejavniki tveganja
English: Change day adjustment
Slovenian: Prilagajanje dneva zamenjave